Pacific Biosciences Of California, Inc. (PACB) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Pacific Biosciences Of California, Inc. (PACB) stock forecast summary
Our AI scores Pacific Biosciences Of California, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Pacific Biosciences Of California, Inc. is a small-cap company with a market capitalization of $755M. It ranks number 12 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
For PACB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -25.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PACB included.
PACB price chart and AI forecast
How PACB ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Pacific Biosciences Of California, Inc. (PACB) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | PACB | Rank |
|---|---|---|
| Market Cap | $755M | 12/25 |
| EPS | $-0.23 | – |
| Revenue/Share | $0.52 | – |
| FCF/Share | $-0.46 | – |
Profitability & Margins
| Metric | PACB | Rank |
|---|---|---|
| ROIC | -20.0% | 13/20 |
| Gross Margin | 34.4% | 16/19 |
| Operating Margin | -81.3% | 14/21 |
| EBT Margin | -80.9% | 16/22 |
| Tax Rate | -0.6% | – |
Financial Health
| Metric | PACB | Rank |
|---|---|---|
| Current Ratio | 4.62x | 8/25 |
| Quick Ratio | 3.72x | 9/24 |
| Interest Coverage | -5.0x | 9/21 |
| Working Capital | $241M | 11/25 |
Cash Flow
| Metric | PACB | Rank |
|---|---|---|
| Operating Cash Flow | -$137M | 23/24 |
| Free Cash Flow | -$143M | 19/20 |
| Capital Spending | -$6M | 12/20 |
| FCF/Sales | -88.8% | 15/19 |
| CapEx/Sales | 4.0% | 6/19 |
Operational Efficiency
| Metric | PACB | Rank |
|---|---|---|
| Asset Turnover | 0.22x | 18/20 |
| Receivables Turnover | 4.2x | 16/19 |
| Inventory Turnover | 1.8x | 13/19 |
| Fixed Assets Turnover | 5.5x | 9/21 |
| Days Sales Outstanding | 87 days | 4/19 |
| Days Inventory | 208 days | 7/19 |
| Payables Period | 38 days | 13/18 |
| Cash Conversion Cycle | 257 days | 3/17 |
Income Statement
| Metric | PACB | Rank |
|---|---|---|
| Total Revenue | $161M | 11/21 |
| Operating Income | -$131M | 19/21 |
| R&D Expense | $86M | 10/21 |
| SG&A Expense | $128M | 13/20 |
| Cost of Goods Sold | $106M | 9/19 |
Dividend & Shareholder Information
| Metric | PACB | Rank |
|---|---|---|
| Shares Outstanding | 311M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $308M | 42.7% of assets |
| Cash & Short-term Investments | $56M | 7.8% of assets |
| Accounts Receivable | $38M | 5.3% of assets |
| Inventory | $60M | 8.4% of assets |
| Total Liabilities | $782M | |
| Short-term Debt | $56M | 7.7% of assets |
PACB quarterly financials and insider trading
Pacific Biosciences Of California, Inc. (PACB) industry peers
Companies classified under the same SEC industry code as Pacific Biosciences Of California, Inc. (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PACB Pacific Biosciences Of California, Inc. | $755M | |
| A Agilent Technologies, Inc. | $49.27B | |
| WAT Waters Corp /De/ | $44.51B | |
| MTD Mettler Toledo International Inc/ | $33.64B | |
| ILMN Illumina, Inc. | $32.23B | |
| RVTY Revvity, Inc. | $17.31B | |
| AVTR Avantor, Inc. | $10.48B | |
| BIO Bio-Rad Laboratories, Inc. | $10.20B | |
| BRKR Bruker Corp | $9.34B | |
| TXG 10x Genomics, Inc. | $7.72B | |
| ALMR Alamar Biosciences, Inc. | $1.95B | |
| CTKB Cytek Biosciences, Inc. | $758M | |
| MASS 908 Devices Inc. | $436M | |
| NAUT Nautilus Biotechnology, Inc. | $284M | |
| BFNH Bioforce Nanosciences Holdings, Inc. | $210M | |
| QTRX Quanterix Corp | $131M | |
| SEER Seer, Inc. | $90M | |
| HBIO Harvard Bioscience Inc | $39M | |
| RPID Rapid Micro Biosystems, Inc. | $35M | |
| PRPO Precipio, Inc. | $33M | |
| EYPT Eyepoint, Inc. | $31M | |
| BNGO Bionano Genomics, Inc. | $13M | |
| LCTC Lifeloc Technologies, Inc | $9M | |
| ASTC Astrotech Corp | $8M | |
| SCND Scientific Industries Inc | $7M |
Where PACB sits on the market map
Pacific Biosciences Of California, Inc. (PACB) stock news
Loading...
Pacific Biosciences Of California, Inc. (PACB) stock forecast FAQ
What is the Pacific Biosciences Of California, Inc. (PACB) stock forecast?
Our AI scores Pacific Biosciences Of California, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Pacific Biosciences Of California, Inc. stock predictions?
For PACB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -25.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pacific Biosciences Of California, Inc. forecasts updated?
Pacific Biosciences Of California, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Pacific Biosciences Of California, Inc.'s industry peers?
25 issuers in our coverage, PACB included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Mettler Toledo International Inc/ (MTD), Illumina, Inc. (ILMN), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.